Militia Capital Partners LP Buys 20,000 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Militia Capital Partners LP has increased its stake in Cellebrite DI Ltd. ($CLBT) by 100%, now holding a total of 40,000 shares valued at approximately $777,000.
• Other institutional investors such as Northern Trust Corp and Bank of America Corp DE have also significantly raised their positions in Cellebrite, demonstrating strong investor interest.
• Cellebrite DI reported quarterly earnings of $0.12 per share, surpassing expectations, with revenue increasing 18.4% year-over-year to $113.28 million.

Militia Capital Partners LP lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 100.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 40,000 shares of the company's stock after acquiring an additional 20,000 shares during the period. Militia Capital Partners LP's holdings in Cellebrite DI were worth $777,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Northern Trust Corp raised its position in Cellebrite DI by 113.6% in the 4th quarter. Northern Trust Corp now owns 211,994 shares of the company's stock worth $4,670,000 after purchasing an additional 112,731 shares during the period. Bank of America Corp DE raised its position in Cellebrite DI by 32.0% in the 4th quarter. Bank of America Corp DE now owns 680,375 shares of the company's stock worth $14,989,000 after purchasing an additional 165,116 shares during the period. Lazard Asset Management LLC raised its position in Cellebrite DI by 3.7% in the 4th quarter. Lazard Asset Management LLC now owns 197,488 shares of the company's stock worth $4,350,000 after purchasing an additional 7,058 shares during the period. Nuveen Asset Management LLC raised its position in Cellebrite DI by 38.5% in the 4th quarter. Nuveen Asset Management LLC now owns 585,839 shares of the company's stock worth $12,906,000 after purchasing an additional 162,886 shares during the period. Finally, Man Group plc purchased a new position in Cellebrite DI in the 4th quarter worth $2,385,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $17.18 on Friday. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company's 50-day moving average is $15.15 and its 200 day moving average is $16.98. The stock has a market capitalization of $4.11 billion, a P/E ratio of -22.61, a P/E/G ratio of 3.11 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. During the same quarter in the previous year, the company earned $0.10 earnings per share. Cellebrite DI's quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CLBT shares. Lake Street Capital decreased their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Finally, Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of "Buy" and an average price target of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.